CMS Reconsiders Medicare Coverage for TAVR in Asymptomatic Aortic Stenosis Patients Following Edwards' Request
核心洞察
The Centers for Medicare and Medicaid Services (搜索) will reconsider its national coverage determination for transcatheter aortic valve replacement (搜索) following Edwards Lifesciences (搜索)' request to expand coverage to asymptomatic patients with severe aortic stenosis (搜索).
Edwards received FDA approval in May for its Sapien 3 (搜索) heart valve in asymptomatic patients based on the Early TAVR (搜索) clinical trial, which showed better outcomes compared to clinical surveillance.
Medical experts remain divided on the expansion, with some supporting evidence-based coverage while others caution against premature implementation due to concerns about long-term durability and study limitations.
The Centers for Medicare and Medicaid Services (搜索) announced it will reconsider its national coverage determination for transcatheter aortic valve replacement (搜索) (TAVR (搜索)) following a formal request from Edwards Lifesciences (搜索) to expand Medicare coverage to asymptomatic patients with severe aortic stenosis (搜索). The agency's decision, posted on Monday, comes after Edwards received FDA approval in May for an expanded indication of its Sapien 3 (搜索) heart valve in this patient population.
FDA Approval Based on Early TAVR Trial Results
Edwards' request centers on results from its Early TAVR (搜索) clinical trial, which demonstrated that asymptomatic patients with severe aortic stenosis (搜索) had better outcomes after TAVR procedures compared to those managed under clinical surveillance, also known as watchful waiting. The study results, released in October 2024, formed the basis for the FDA's approval of the expanded indication for the Sapien 3 (搜索) device.
The condition involves a narrowing of the heart's aortic valve (搜索) that reduces blood flow to the body. Currently, Medicare coverage for TAVR (搜索) is limited to symptomatic patients, leaving asymptomatic cases outside the scope of reimbursement.
Market Impact and Analyst Projections
Industry analysts anticipate significant market expansion if Medicare coverage is approved. William Blair analyst Brandon Vazquez noted that one-third of severe aortic stenosis (搜索) patients are estimated to be asymptomatic. BTIG analyst Marie Thibault suggested that updating the TAVR (搜索) national coverage determination could improve efficiency in existing centers and potentially lead to the establishment of new TAVR centers.
Edwards expects the updated labeling to accelerate sales of the device, with broader reimbursement potentially driving further adoption across healthcare systems.
Medical Community Divided on Coverage Expansion
The medical community has expressed mixed views on Edwards' request. Five major heart societies, including the Society of Thoracic Surgeons (搜索), American Association for Thoracic Surgery, American College of Cardiology (搜索), Heart Failure Society of America, and Society for Cardiovascular Angiography and Interventions, recommended that CMS update its TAVR (搜索) national coverage determination to include FDA-approved indications.
"As TAVR (搜索) has become integral to the care of patients with AS, the impact of an updated NCD will be profound and far-reaching, influencing not only patients who undergo TAVR but also the broader systems of care for all individuals with aortic valve (搜索) disease," the groups wrote.
Concerns About Premature Implementation
However, several experts have raised concerns about expanding coverage without additional evidence. Steven Woloshin of the Dartmouth Institute for Health Policy and Clinical Practice cautioned, "TAVR (搜索) may ultimately have a role for asymptomatic patients — but we just don't know yet. Until we do, it is premature to change practice."
Diana Zuckerman, president of the nonprofit National Center for Health Research, argued that the Early TAVR (搜索) trial data cannot be generalized to most Medicare beneficiaries because study participants were predominantly at low risk for surgery. She expressed concerns about the durability of earlier bioprosthetic valve implantation and the risk of repeat interventions over a beneficiary's lifetime.
"Given the problems with the study design, CMS should be reluctant to make a coverage decision that would encourage Medicare asymptomatic beneficiaries to earlier lifelong device implantation, potential re-interventions, and downstream complications without clear evidence of survival or disability benefit," Zuckerman wrote.
Coverage with Evidence Development Debate
Edwards also requested the removal of coverage with evidence development (CED) requirements, which the company views as creating barriers to care. CED is a program that allows Medicare coverage while requiring participation in clinical studies.
Joseph Sabik, president of the Society of Thoracic Surgeons (搜索), urged CMS to maintain its CED policy for TAVR (搜索), stating that while emerging trial data suggests potential benefit in select patients, "treatment should be limited to carefully defined populations evaluated by a multidisciplinary Heart Team, with shared decision-making and continued evidence development to avoid inappropriate expansion and overtreatment."
Medtronic Vice President Jeff Farkas noted that long-term data are not yet available for the asymptomatic population, cautioning that "the ability to diagnose asymptomatic aortic stenosis (搜索) and existing clinical guidelines are not yet mature enough for CMS to use for coverage without additional evidence development."
CMS Review Process
In announcing its reconsideration, CMS indicated it would analyze the clinical evidence for characteristics that make patients more or less likely to benefit from TAVR (搜索) devices and whether specific treatment conditions are necessary to achieve the outcomes demonstrated in studies.
Edwards Vice President Daniel Lippis maintained that aligning TAVR (搜索) coverage with approved FDA indications remains a priority. "Edwards believes updating this NCD will not only advance care, but will also improve patient outcomes, provide equitable access for all patients with AS, and reduce long-term Medicare costs," Lippis wrote.